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Successful strategies for renal transplantation in primary oxalosis.
Eleven patients, aged 6 months to 47 years, with renal failure due to
primary oxalosis, received renal allografts and were followed for 1 to 9
years. A specialized strategy for medical management included inten-
sive pre-transpiant hemodialysis and post-transplant long-term diuresis,
administration of neutral phosphate, Mg and pyridoxine. Seven of
ten living-related (LRD) transplants have good renal function, six with
no biopsy evidence of renal oxalate deposition at up to 7 years after
transplant. Two LRD graft losses from recurrent oxalosis, accompanied
by massive secondary oxalate deposits, occurred in patients following
endstage renal failure for over 3 years. A third LRD graft loss occurred
following long-term (6 month) peritoneal dialysis in an infant. One
cadaver transplant recipient has survived with recurrent oxalosis and
poor graft function for 9 years. It is possible to perform successful renal
transplantation in small children and adults with primary oxalosis and to
completely prevent the deposition of oxalate in the renal allograft.
Renal transplantation, with a strict medical protocol, would appear to
be the initial treatment of choice for renal failure due to primary
oxalosis.
Strategies réussies de transplantation renale au cours de l'oxalose
primitive. Onze malades, âgés de 6 mois a 47 ans, atteints d'insuffisance
rénale par oxalose primitive, ont recu des allogreffes rénales, et ont été
suivis de I a 9 ans. Une strategie spécialisée de soin medical compren-
nait une hémodialyse pre-transplantation intensive et une diurèse post-
transplantation a long terme, l'administration de phosphates neutres, de
Mg , et de pyridoxine. Sept des dix transplants de donneurs vivants(LRD) avaient une boone fonction rCnale, dont six sans evidence
biopsique de depot renal d'oxalate jusqu'à 7 ans aprés Ia transplanta-
tion. Les deux pertes de greffons LRD par oxalose récidivente, accom-
pagnées par des dépôts massifs secondaires d'oxalates, sont survenues
chez des malades après une insuffisance rénale terminale pendant plus
de 3 ans. Un troisième perte de greffon LRD est survenue aprCs a long
terme (6 mois) dialyse peritoneal dans un petit enfant. Un receveur de
transplant de cadavre a survécu avec une oxalose récidivante et une
fonction du greffon mediocre pendant 9 ans. 11 est possible de faire une
transplantation rénale réussie chez de petits enfants et chez des adultes
atteints d'oxalose primitive, et de prCvenir complètement le dépôt
d'oxalate dans l'allogreffon renal. La transplantation rénale, avec un
protocole medical strict, pourrait apparaitre comme le traitement initial
de choix de l'insuffisance rénale par oxalose primitive.
Primary hyperoxaluria (oxalosis) is a rare cause of endstage
renal failure (ESRF). The Registry of the European Dialysis and
Transplant Association (REDTA) recorded only 76 new pa-
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tients entered into treatment in the 8 years from 1973 to 1980
[1]. Most of these new patients were treated by hemodialysis
alone perhaps because of previous reports indicating poor
results of transplantation, with almost universal and rapid
recurrence of disease in the renal allograft [2—51. Life table
analysis of 95 accumulated patients (most on long-term hemodi-
alysis) projected a 50% survival at 5 years [1], but the quality of
life for these patients has not been satisfactory: All children on
any form of treatment had severe bone disease 2 years after
diagnosis of ESRF from oxalosis, raising the question as to
whether any form of ESRF therapy in oxalosis was justified in
children [61 or adults [7].
However, prevention of progressive renal failure in primary
hyperoxaluria can be successful, if the diagnosis is recognized
before the onset of renal insufficiency and if aggressive medical
management is instituted [8]. We have therefore accepted
patients for transplantation and have attempted to prevent
recurrent oxalate deposition in the allograft by utilizing a similar
aggressive medical management protocol. We report here the
results of this systematic approach in eleven patients with renal
failure due to primary hyperoxaluria. While the specific value of
individual components of the protocol used could not be
evaluated, we conclude that aggressive medical preparation and
treatment can be effective in avoiding recurrence of oxalosis in
the renal allograft in selected adults and children. Other second-
ary complications can also be prevented. For these patients,
renal transplantation is the treatment of choice.
Standard treatment protocol
The following protocol, considered 'standard," was utilized
to avoid recurrence of oxalosis in the renal allograft. Individual
exceptions were necessitated by cadaver transplantation, he-
modialysis access problems, or post-transplant complications.
(1) Aggressive hemodialysis at a urea clearance greater than
3 mI/mm/kg for 4 to 6 hr, daily, for 5 to 10 days prior to
transplantation, in an attempt to remove as much oxalate as
possible from a hypothesized large exchangeable oxalate pool.
(2) Transplantation from as well-matched a donor as possi-
ble, to decrease the risks of early post-transplant acute renal
failure (ARF), and acute rejection episodes.
(3) Immediate post-transplant institution (intravenously) of
pyridoxine (> 0.5 g/l .73 m2/day), neutral phosphate (2 g ele-
mental P/1.73 m2), Mg, (5 to 10 mEq/l.73 m2/day), non-
calciuric diuretics (chlorothiazide, 50 mg/day), and fluids to a
maximum tolerated without marked elevation of central venous
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pressure or systemic BP. Serum Ca was maintained between
7.5 and 9.5 mgldl to avoid the risk of clinical hypocalcemia or of
metastatic calcifications.
(4) Following transplantation, oral pyridoxine, neutral phos-
phate (K-Phos Neutral, Beach Pharmaceuticals, Tampa, Flori-
da) and Mg (Mg oxide or gluconate, 0.5 to 2 g/day) were
gradually substituted for intravenous medications usually over
2 to 3 weeks, to avoid diarrhea. Thus, total daily doses of these
medications were not decreased. Careful monitoring of serum
Ca to achieve a level of 8 to 9.5 mg/dl, Mg to a maximum
serum level of 3 mEq/liter and P to a maximum of 6.5 mg/dl
guided the adjustments in these medications to a maximum
tolerated dose. Ca or vitamin D supplements were given only
for serum values of less than 8 mg/dl.
(5) Institution of immediate and vigorous hemodialysis, in
the event of a decrease in allograft function, until renal function
returned, as reflected in a serum creatinine of less than 3.0
mg/dl.
Intravenous, followed by oral, alanine was used only in our
first patient (number 6) at 5 to 10 g/day, because of encouraging
experimental data [9]. Methylene blue [101, 90 to 360 mg/day,
was also used for several years in patient 6, and for only 2
weeks in patient 2; it was discontinued because of possible
psychiatric side-effects.
Methods
The surgical procedures for renal transplantation and the
post-transplant protocols for immunosuppression with antilym-
phoblast globulin, Imuran and prednisone, have previously
been reported from the University of Minnesota Hospital
(UMH), Minneapolis, Minnesota [11, 12]. Splenectomy was
performed in all patients and bilateral nephrectomy in all but
three (patients 5, 7, and 8). Methoxyflurane anesthesia [5] was
avoided for all surgery.
Twenty-four hour urinary oxalate and dialysate oxalate con-
centrations were determined by the method of Hodgkin son and
Williams [131 by Ms. Doris Doeden (Department of Pediatrics,
UMH) or by Bioscience Laboratories (Van Nuys, California).
Because of the marked differences in body size and muscle
mass among the patients, serum creatinine was converted to
mg/dl/l.73 m2 and referred to as corrected creatinine (CorCr).
This correction has a good correlation with glomerular filtration
rate (GFR) [141.
Percutaneous transplant biopsies were performed and tissue
was processed routinely for light, immunofluorescence, and
electron microscopy. A direct comparison of paraffin sections
with unfixed frozen sections showed no loss of polarized
crystals with hematoxylin and eosin (H & E) stained sections,
while periodic acid-Schiff- and trichrome-stained sections
showed markedly diminished oxalate crystals. To quantitate
oxalate crystals, H & E sections were examined under polar-
ized light blindly with a microscope (Zeiss Ultraphot) at x500.
Full, non-overlapping cortical fields were examined, and the
number of tubular cross sections containing oxalate crystals
were counted and scored: A score of 3 was assigned for crystals
that filled the entire tubule, a score of 1 for crystals occupying
no more than 5 to 10% of the tubule, and a score of 2 for
intermediate amounts of oxalate. The total number of oxalate-
containing tubule cross-sections times crystal scores, divided
by the number of cortical fields studied (5 to 20), was expressed
Table 1. Patients transplanted for primary hyperoxaluria
Age at
Age of renal Age at
Patient onset Presenting failure transplant Donor
no. years features years years sourceb
1 2.5 Stones 25 26 Sib (HLA-Id)
2 22 Stones 46 47 Sib (2 ag)
3 7 Uremia 7 8 Parent
4 0.3 Uremia 0.3 0.5 Parent
5 0.5 Uremia 0.8 1.3 Parent
6 5 Uremia 5 5.5 Cad (2 ag)
7 7 Stones 19 22 Parent8 15 Stones 26 30 Parent
9 0.25 Uremia 0.25 0.9 Parent
10 0.15 Uremia 0.15 0.6 Parent
11 3 Stones 24 24 Sib (2 ag)
Two
oxalosis.
previous cadaveric transplants lost rapidly to recurrent
b Ag represents antigen-match.
as the biopsy score. The average biopsy score for six pre-
transplant nephrectomy specimens (three infants, two children,
one adult) was 29.4 12.7 (x SD) and is taken as the score
representing endstage disease for native kidneys.
Results
Patient population and clinical description
Kidney transplants have been performed at the UMH in 11
patients with primary hyperoxaluria who were treated with the
standard management protocol and for whom adequate follow-
up (at least 9 months or to allograft failure) has been available
(Table 1). The age of onset of ESRF ranged from 4 months to 46
years. Two patients had a history of fatal oxalate disease in a
sibling. All 11 patients had the onset of clinical disease in
childhood. In the adult transplant recipients, despite many
years of nephrolithiasis, the final progression from relatively
normal renal function to ESRF occurred over less than 2 years.
The children presented with ESRF without a history of stone
disease.
Urinary oxalate excretion was elevated in our patients prior
to transplantation (Table 2). There was a progressive decrease
in urinary oxalate excretion in seven of eight patients studied
sequentially during the first 6 months following trasplantation.
Evidence of extrarenal deposition of oxalosis was apparently
related to age at onset and duration of renal failure: Three of the
four children presenting with renal insufficiency before 1 year of
age (patients 5, 9, and 10, Table 1) had retinal lesions [15] and
significant oxalate deposits on bone biopsy, when studied after
6 months of established ESRF. The infant, patient 4, without
extra-renal oxalate deposits had clinical evidence of renal
insufficiency for less than 2 months at the time of evaluation.
No patient over 1 year of age at presentation of ESRF had
significant retinal deposits, but bone marrow biopsy specimens
of the older children (patients 3 and 6) showed oxalate deposits
after less than 1 year of ESRF. Peripheral neuropathy, more
severe than expected for uremia alone, was present in four
adults soon after ESRF. Long-term ESRF requiring dialysis for
more than 3 years preceeded transplant in two adult patients (7
and 8). Both were clinically crippled from extensive oxalate
deposits in skin and joints and had severe vascular insufficien-
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Table 2. Urinary oxalate excretion, sequence of values obtained
Patient no.
Oxalate excretion
mg/24 hr/i .73 m2
Pre-transpiant (—months) Post-transplant (months)
1
2
3
4
5
6
7
8
9
10
11
300 (—10)
208 (—12)
(t)a(_12)
(1' )a (—2)
160 (—6) 74 (—2)
208 (—4) 1250 (—0.5)
U )a (—30)(f)a(24)
( ) (—6)
215 (0.25)
150 (24)
656 (1)
277 (3)
450 (0.3)
865 (1)
700 (0.05)
200 (2) 120(6)
892 (1.5) 300(3)
360 (12)
207 (6)
590 (3) 415 (4)
490 (1) 360 (2)
550 (0.01) 275 (2)
915 (0.01) 668 (0.1)
502 (0.05)
178(65)
195 (4)
270 (8)
464 (3)
a Elevated values were obtained elsewhere, so that methods and precise values are not comparable.
cy. One had recurrent ventricular tachycardia, presumed to be
secondary to myocardial oxalate deposition.
Results of transplantation (Table 3)
Ten patients received living-related donor (LRD) transplants,
eight within 1 year of ESRF. These eight patients were hemo-
dialyzed, six very aggressively, prior to transplantation. All
received the standard protocol after transplantation. Seven
exhibit satisfactory allograft function (Fig. 1).
Two patients received LRD transplants after more than 3
years of dialysis. As noted above, both developed massive
secondary depositions of oxalate prior to transplantation. Pa-
tient 8 lost two cadaver transplants at other institutions from
recurrence of oxalosis in the allografts. Because of vascular
access difficulties, this patient received only peritoneal dialysis
prior to the third (LRD) transplant. Despite the standard post-
transplant protocol, allograft renal function was slowly lost due
to recurrent disease over 3 months. Similarly, the second
patient (number 7) transplanted after more than 3 years of
dialysis slowly lost renal function over the first 3 months after
the transplant, despite complete adherence to the standard
protocol. Hemodialysis was then reinstituted to maintain the
predialysis serum creatinine at 3.0 mgldl. Both patients had
dramatic shrinkage of dermal and joint deposits over the first 2
months after transplantation while their CorCr were still less
than 3 mg/dl. A third patient (number 9) was routinely peritone-
ally dialyzed for 6 of 9 months prior to transplant, and despite
aggressive pretransplant hemodialysis developed early progres-
sive renal oxalate deposition.
A 5-year-old child (number 6) received both kidneys from a 5-
year-old cadaver donor. This patient had delayed initial allo-
graft function (ARF), then rejection, and later obstructive and
infectious allograft complications. Her long-term course was
that of progressive loss of renal function with each complication
(Fig. 1) and biopsy-documented recurrence of renal oxalosis
(see below). She continued to suffer from progressive and
crippling secondary complications of disseminated oxalosis
[16]. Thus, while persistent therapy according to the protocol
may have allowed 9-year graft survival of a patient whose
native kidneys were lost at age 5, this transplant is considered a
failure.
The courses of the nine patients with long-term renal function
are depicted in Figure 1, related to CorCr. Note that patient 5,
whose uncorrected serum creatinine continued at 1.2 mg/d!, had
an elevated CorCr, reflecting a relative diminution in renal
function. Despite this she has had normal growth and develop-
ment. This patient had gradual but significant improvement in
renal function over the 4 months following resolution of initial
obstructive and infectious complications in the allograft. This
improvement and later stability occurred despite severe oxalate
deposition seen on transplant biopsy specimens. Patient 6
clearly had renal function (serum creatinine 3.0, CorCr 7.5, at 8
years post-transplantation) that was inadequate to prevent
disseminated oxalosis. The courses of the six other patients
have been remarkably stable and uneventful.
The seven patients with long-term functionally successful
transplants ranged in age at transplant from 6 months to 47
years. Therapy of these seven patients varied according to
patient tolerance. Most consistently, urine output was main-
tained at 50 to 100 mllkg/day. Pyridoxine was taken in doses of
at least 500 mg/l.73 m2/day. Phosphate supplements have
varied from 20 to 50 mg elemental P/kglday, depending on
diarrhea and hyperphosphatemia. The longest successful survi-
vor, patient 1, took only 750mg P over the last 2 of 7 years, due
to severe diarrhea resulting when oral phosphate was combined
with lithium therapy for an affective disorder. With the excep-
tion of this patient, Mg supplements (0.5 to 2 g/day) were
given consistently. The hypercalciuric effect of diuretics was
minimized by the use of thiazides, except in patient 1, who
always maintained a low calcium diet and a high urine output
(4000 mllday) without diuretics.
Renal biopsy results
Biopsies were performed in most patients within 5 weeks of
transplantation, again at 3 to 6 months, and thereafter at 1- to 2-
year intervals. Six of the seven biopsied patients with function-
ally successful (LRD) grafts had scores less than 2.0 on all
transplant biopsy specimens, and no oxalate (score = 0) on the
most recent biopsy specimen (at 0.35, 0.25, 1, 1.5, 2, 3, and 7
years). The predictive value of the biopsies in the first six
patients (1 to 6) with long-term graft function was seen by a high
correlation (r = +0.90, P < 0.001, N = 22) between all scores
and the last CorCr (Fig. 2). Most patients had more than one
biopsy in the first 6 months post-transplantation. The mean of
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Table 3. Course after transplantation for primary hyperoxaluria
Pa- Preparation
Early course (2 months) Late course
Imme- Outcome
tient pre diate Oxalosis Compli-
no. transplant function Complications therapy-initial cations Months Function Comments
I Aggressive Excellent Bowel obstruction Begun at 10 None 84 Excel- Several stones passed 1st year and
HD for 10 days days lent 1 stone at 84 months; affective
disorder now requires lithium,
with decreased tolerance to oral
phosphate
2 Routine HD Excellent ALG reaction at 3
weeks Dialysis
x 2 weeks
Suspended dur-
ing the 2-wk
dialysisa
None 39 Excel-
lent
Hypertension, controlled
3 Aggressive Excellent None Standard None 24 Excel- Growth normal, radiographic bone
HD lent oxalosis healed at 2 years, oxa-
late deposits remain in bone
biopsy
4 Aggressive Excellent None Standard Sepsis at 16 18 Excel- Growth normal; bone biopsy re-
HD months,
rapid re-
covery
lent mains normal at 6 months,
radiographic bone oxalosis
improvede5 Aggressive Excellent Multipleo Suspended for 2 None 30 Good Growth normal, radiographic bone
HD weeks during
complications
oxalosis improved, oxalate re-
mains in bone biopsy
6 Routine HD Fair ARF, dialysis for 6
days; rejection
at 6 weeks; hem-
orrhage and
shock at 2.5
months
Suspended dur-
ing complica-
tionsab
Multiple' 96 Poor No growth; multiple fractures,
crippling bone disease
7 Aggressive Excellent None Standard N/A 5 Poor Cr 3.0 mg/dl, on dialysis; urine
HD volume 2000 mi/day; standard
protocol continues
8 Routine PD Excellent E. coli pyelone-
phritis
Standard N/A 5 None Died on dialysis at 1 year
9 Aggressive Excellent None Standard Pseudotu- 12 Poor Progressive renal oxalate deposi-
HD mor cere-
bri at 6
months
tion over first 12 months, re-
transplant advised
10 Aggressive Excellent None Standard None 12 Excel- Growth normal, radiographic bone
HD lent oxalosis improved; renal biopsy
at 3 months—NO oxalate
deposition
11 Aggressive Excellent None Standard None 9 Excel-
HD lent
Abbreviations: HD, hemodialysis; ALG, antilymphocyte globulin; ARF, acute renal failure (delayed function); PD, peritoneal dialysis.
aThe patient was also given methylene blue.
The patient was also treated with alanine.
Complications included ureteral obstruction, requiring two operations and dialysis; Candida pyelonephritis.' Complications included rejection at 4.5 months; obstruction and infection at 20 months; ureteral reimplantation at 26 months; ureteral
obstruction at 56 months.
Patient 4 developed severe hypertension at 22 months, associated with (uncorrectable) intrarenal vascular stenosis; a retransplant is planned.
Patient 5 developed pseudotumor cerebri at 36 months, requiring a ventriculo-peritoneal shunt.
the scores for each of these first six patients was also correlated
highly with their last CorCr (r = +0.98, P < 0.001). For a
patient with graft function at 6 months, a single score of 2.0 or
less would predict (P < 0.05) a final CorCr of less than 4 mg/dl.
Although there was a significant correlation between the scores
for all biopsy specimens for all patients, that is, 1 to 8, and the
last CorCr, this relationship was not precise (r = +0.55, P <
0.001, N = 34).
There was no significant correlation between all biopsy
scores and concurrent CorCr (r — +0.11, N = 34), even for
patients ito 6 who had long-term graft survival, (r = +0.18, N
= 22). For example, patient 1 had a small amount of oxalate on
biopsy at 5 months (Fig. 3, score 1.8) which was considerably
less at 5 years (Fig. 4, score 0.2) and no oxalate in the biopsy
specimen at 7 years. At 5 months patient 6 had a score of 30,
with a moderately elevated concurrent CorCr of 3.0 mg/dl, a
similar score (31.5, Fig. 5), but a more severely elevated CorCr
of 4.7 at 2.5 years, and a final CorCr 7.5 mg/dl at 8 years. Patient
5 had a biopsy score of 3.3 at 3 weeks, 5.6 (Fig. 6) at 5 weeks
and 12.5 at 6 weeks, concurrent with several renal complica-
tions. The scores for patient 5 related better to the last (2 year)
CorCr value of 4.2 mg!dl than to the concurrent CorCr of 9.5
mg/dl. Despite stable function and excellent overall clinical
course, the last biopsy specimen from patient 5 at 2 years had a
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Time, post-transplant
Fig. 1. Courses of nine patients with primary oxalosis having long-term
renal allograft function. Adults (—)and children (----) are indicated,
identified by numbers from Tables 1—3. Note three divisions in time
scale.
score of 22.8, similar to scores in "endstage" oxalosis kidneys.
Thus, we found that biopsy scores were only predictive of long-
term function.
The early (less than 6 month) loss of graft function in the two
transplants that followed long-term dialysis was poorly related
to early biopsy scores. These biopsy specimens generally
showed only moderate oxalate deposition (scores 0.7 to 7,2)
even while developing renal functional deterioration that could
not be explained by causes other than hyperoxaluria.
Discussion
This report demonstrates that it is possible to perform
succesful renal transplantation in small children and adults with
primary oxalosis and to completely prevent the deposition of
oxalate in the renal allograft.
Eleven patients have been transplanted with the use of the
standard protocol. Seven of ten LRD transplant patients with
adequate follow-up have satisfactory renal function; six have no
evidence of oxalate deposition on biopsy up to 7 years after
transplantation. The two adults who were LRD transplant
patients and whose renal function was lost due to oxalosis had
been in ESRF for more than 3 years prior to transplantation; a
third LRD transplant patient, an infant, was on long-term
peritoneal dialysis (CAPD) for 6 months. One cadaver allograft
recipient treated by the standard protocol has lost function due
to complications of transplantation and to recurrent oxalate
deposition.
We believe that success has been due to the systematic
application of a protocol derived from strategies successful in
preventing recurrent nephrolithiasis and the progression of
primary hyperoxaluria to renal insufficiency in patients with
intact renal function. The contributions of the individual ele-
'V//////
0 10 20 30
Biopsy score
Fig. 2. Relationship ofall biopsy scores in six patients with long-term
allograft function, to CorCr at final outcome (last follow-up). Total
number of points is 22, with 15 scores under 2.0. The regression line is
indicated for r = +0.90. The range of biopsy scores for patients 5
(CorCr 4.2) and 6 (CorCr 7.5) can be seen.
Fig. 3. Renal allograft biopsy in patient 1 at 5 months after transplanta-
tion, viewed with polarized light. The score is 1.8 (X 160)
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ments of the protocol cannot be proven but can at least be
rationalized: The inhibition of the crystallization of calcium
oxalate in the urine should require a large urine volume, which
decreases the concentration of oxalate, and thus the supersatu-
ration of the urine with respect to calcium oxalate [171. This has
been effected by increased fluid intake supplemented with non-
calciuric diuretics (hydrochlorothiazide, metolazone [18]). Or-
thophosphate supplements can decrease calcium oxalate super-
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Fig. 4. Renal allograft biopsy in patient I at 5 years after transplanta-
tion, viewed with polarized light. The score is 0.2, although no oxalate
crystals are visible in this field. (x160)
saturation [8] by decreasing urinary and increasing
phosphate, citrate, and urinary pyrophosphate, which inhibits
the growth of calcium oxalate crystals [19, 20]. Mg forms a
soluble complex with oxalate in the urine [20] and can prevent
stone formation in primary hyperoxaluria [21, 221. Dietary salt
should be liberal to increase urinary Na [8] and avoid volume
depletion. Dietary Ca should not be severely limited, to
avoid oxalate hyperabsorption [8]. Pyridoxine has been given in
pharmacologic doses but would be expected to be of great value
only in the rare case of pyridoxine-dependent oxalosis [23].
These elements of the standard protocol were combined with
strategies to protect the transplanted kidney not only from the
primary disease, but also from the added danger of markedly
elevated levels of plasma oxalate [24, 25] and the release of
oxalate from extrarenal deposits accumulated during renal
insufficiency. We have chosen to aggressively hemodialyze
patients prior to transplantation with the hope of reducing
plasma oxalate and, perhaps, effecting at least a partial deple-
tion of oxalate stores. Although the maximum amount of
oxalate removed during a single hemodialysis, in the range of
500 mg (unpublished data), may not significantly decrease total
stores, an exchangeable store may exist that could be presented
to the newly transplanted kidney. Daily hemodialysis can be
performed at higher than normal (3 mI/mm/kg) clearance with-
out disequilibrium [261. This (hemodialysis) protocol cannot be
used for cadaver transplants, so we have chosen a living-related
transplant whenever possible. In addition, rejection episodes
may be less frequent in LRD transplants [11].
Previous reports of the results of renal transplantation in
primary hyperoxaluria are difficult to evaluate because of the
small numbers of patients from any institution, the lack of a
strategy directed to preventing recurrent oxalate deposition,
and the absence of histologic data concerning recurrent oxalate
deposition [27, 28]. A favorable outcome in the unusual patient
might result from a dramatic decrease in oxalate production
after pyridoxine therapy [23]. Long-term graft function alone
does not constitute success, as exemplified by the tragic course
of patient 6, reported elsewhere [16], who has become severely
crippled from progressive oxalate bone disease which was
exhibited after transplantation.
Fig. 5. Renal allograft biopsy in patient 6 at 2.5 years after transplanta-
tion, viewed with polarized light. The score is 31.5. (XlOO)
Fig. 6. Renal allograft biopsy in patient 5, 5 weeks after transplanta-
tion, viewed with polarized light. The score is 5.6. (x100)
Although one short-term, biopsy-proven transplant success
has been reported after long-term hemodialysis [29], we have
not been successful in the transplantation of patients with
primary hyperoxaluria after more than 3 years of hemodialysis
in adults or long-term peritoneal dialysis in an infant. We
hypothesize that large accumulated stores of oxalate present in
these patients are released following transplantation. In two of
our patients in this category (7 and 8), large superficial deposits
of oxalate crystals were observed to shrink markedly in the first
2 months after transplantation, while renal function was deteri-
orating, but the biopsy scores were not high. In patient 8 whose
oxalate excretion was carefully monitored, extremely large
amounts of oxalate (700 mg, decreasing to 500 mg) continued to
be excreted over those first 2 months (Table 2). This suggests
that released stores provide an extra load of oxalate that may
directly compromise renal function, by unknown mechanisms,
as well as by depositing in the allograft.
Renal biopsy is useful for eliminating causes of decreased
renal function other than oxalate deposition and in predicting a
clinically satisfactory long-term course. Early renal biopsy has
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not allowed the prediction of early loss of renal function due to
hyperoxaluria. Relatively small amounts of early renal oxalate
deposition (scores of less than 2) are compatible with either
early progressive loss of function or with excellent long-term
function and loss of all deposited oxalate. These similar biopsy
findings, with differing renal function and course, suggest that
small quantities of intratubular oxalate deposition per se are not
necessarily responsible for diminished renal function. The
toxicity of oxalic acid (0.2 mM) to endothelial cells in vitro has
been described [301. This level is apparently well tolerated in
the urine of non-hyperoxaluric subjects. However, in patients
with primary hyperoxaluria, who can have urine oxalate con-
centrations in the range of 2 m during the first month after
transplantation, some direct toxic effect might occur.
The complications that can occur after any renal transplanta-
tion have special implications for patients with primary oxalo-
sis. Any cause of decreased renal function might result in renal
oxalate deposition. Our approach has been to reinstitute aggres-
sive supplemental hemodialysis when renal function deterio-
rates from any cause which we did with three patients, without
apparent deleterious effects, as long as doses of phosphate and
Mg were appropriately decreased. Stable renal function is
possible in the presence of some degree of recurrent renal
oxalate deposition. This was seen in patients 5 and 6 and in
patients reported elsewhere [29]. The minimum level of renal
function (and maximum plasma oxalate) that is compatible with
stable renal function, without progressive renal and systemic
oxalate deposition, has not yet been determined.
Renal or systemic oxalate deposits that can occur in long-
standing renal failure not due to primary hyperoxaluria [311 can
usually be excluded by history. Primary hyperoxaluria can only
be diagnosed with certainty by the demonstration of increased
urinary oxalate excretion, a finding which might be lost as renal
insufficiency develops. Thus, certain diagnosis may only follow
transplantation, whose management by our standard protocol,
we feel, nevertheless should carry less risk than that of routine
management in a hyperoxaluric patient.
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